NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against James Hardie Industries plc (NYSE: JHX) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in James Hardie, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/james-hardie-i ...

Accessibility StatementSkip Navigation SAN DIEGO, Dec. 1, 2025 /PRNewswire/ -- Company: James Hardie Industries plc (NYSE: JHX) provides exterior home and outdoor living solutions and markets itself as the number one producer of high-performance fiber cement building solutions in the United States. What is the class period? May 20, 2025 - August 18, 2025 What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Jam ...

Core Viewpoint - Organon & Co. experienced a significant drop in share price following the announcement of an investigation into improper sales practices and the resignation of CEO Kevin Ali, raising concerns about the company's internal controls and financial reporting [1][4]. Group 1: Company Investigation and Findings - An independent internal investigation revealed that certain wholesalers were encouraged to purchase more Nexplanon than needed, particularly at the end of 2022 and throughout 2024 and 2025, which helped Organon meet revenue expectations [4]. - The investigation led to the termination of the Head of U.S. Commercial & Government Affairs and the resignation of CEO Kevin Ali without severance or equity-related retirement benefits [4]. Group 2: Market Reaction and Legal Implications - Following the announcement, Organon's share price fell by $2.10, representing a 23% decrease, indicating severe market reaction to the news [1]. - Hagens Berman, a national shareholders rights firm, has initiated an investigation to determine if Organon and its former CEO misled investors regarding compliance with accounting rules and the effectiveness of internal controls [2][3].